We present a case series of three febrile episodes in neutropenic pediatric cancer patients who wore a Food and Drug Administration approved high-frequency temperature monitoring (HFTM) wearable device (WD) at home.
Fever is an important early sign of serious treatment-related adverse events such as cytokine release syndrome (CRS) caused by chimeric antigen receptor T cell (CAR-T) immunotherapy and such as infection related to chemotherapy induced neutropenia
ABSTRACT Background: Australia has successfully controlled the COVID-19 pandemic. Similar to other high-income countries, Australia has extensively used telehealth services.
Neutropenic fever is a medical emergency in patients (pts) undergoing intensive chemotherapy or stem cell transplant (SCT). Early detection of fever allows for prompt infectious work up and initiation of broad spectrum antibiotics.
Summary: The TOST equivalence test indicates TempTraq® is not equivalent to Pulmonary Artery Catheter. The Bland-Altman test for agreement indicates TempTraq® is in agreement with Pulmonary Artery Catheter and there is an overall bias of .3 between the two measurement systems.
Early detection of fever and prompt use of broad-spectrum antibiotics is crucial in neutropenic patients (pts). Therefore, a continuous real time method of body temperature measurement may serve as a clinical decision support tool to improve outcomes.
Current standard of care (SOC) includes episodic monitoring of temperature in hospitalized patients, which may delay fever detection. Therefore, continuous real-time body temperature measurement may detect fever prior to the current SOC.
The purpose of this study was to assess the accuracy of the TempTraq thermometer as compared to a gold standard (Core temp measured by Pulmonary Artery Catheter) and to assess the precision of the TempTraq thermometer over repeated measures.